• Provision of signed and dated written informed consent prior to any study-specific procedures.

• Adults aged 18-75, inclusive when signing the informed consent.

• Documented physician-diagnosis of asthma for at least 12 months.

• Treated with medium or high dose ICS in combination with LABA.

• Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 .

• Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal.

• Documented exacerbation history in the last 12 months and biomarker requirements of:

∙ 2 severe exacerbations OR

‣ 1 severe exacerbation and:

• (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb

• Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary.

• Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test.

⁃ Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.